Latest S. aureus Stories
CHAPEL HILL, N.C., Oct. 29 /PRNewswire/ -- Cempra Pharmaceuticals today announced data presentations of its lead antibiotic candidate, CEM-102 (fusidic acid), at the Infectious Diseases Society of America, 47th Annual Meeting, Oct. 29 to Nov.
Scientists studying Staphylococcus bacteria, including methicillin-resistant S. aureus (MRSA), have discovered a potent staph toxin responsible for disease severity.
Infectious disease specialists at UT Southwestern Medical Center have mapped the gene profiles of children with severe Staphylococcus aureus infections, providing crucial insight into how the human immune system is programmed to respond to this pathogen and opening new doors for improved therapeutic interventions.
Novel Fluoroquinolone Demonstrates Safety and Efficacy in Treatment of Skin Infections NEW HAVEN, Conn., Jan. 26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.
There is a nationwide increase in the prevalence of pediatric methicillin-resistant Staphylococcus aureus head and neck infections, U.S. researchers said.
Scientists have discovered a new way for bacteria to transfer toxic genes to unrelated bacterial species, a finding that raises the unsettling possibility that bacterial swapping of toxins and other disease-aiding factors may be more common than previously imagined.
WASHINGTON, Oct. 27, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
Targanta Therapeutics Corporation (NASDAQ: TARG) today announced that data describing oritavancin's multiple mechanisms of action and its concentration-dependent bactericidal activity will be delivered at the combined annual meetings of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the 46th Infectious Disease Society of America (IDSA), taking place in Washington, DC, October 25-28, 2008.
ROCKVILLE, Md., Sept.
VIENNA, Austria, Aug. 28 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that its collaborator Merck & Co., Inc. has initiated a Phase II clinical trial of V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infections.
Staphylococcus aureus is a facultative anaerobic gram-positive coccus, and is the most common cause of staph infections. It is commonly part of the skin flora found in the nose and on skin. Around 20% of the human population is long-term carriers. It gets its golden color due to its carotenoid pigment staphyloxanthin. The pigment acts as a virulence factor with an antioxidant action that allows the microbe to evade death by reactive oxygen species used by the host immune system. Staphylococci...
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.